A5000130570- BRCA gene mutations in cancer
- Nutrition, Genetics, and Disease
- Epigenetics and DNA Methylation
- Ovarian cancer diagnosis and treatment
- CRISPR and Genetic Engineering
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Acute Myeloid Leukemia Research
- Genomic variations and chromosomal abnormalities
- Genetic factors in colorectal cancer
- Molecular Biology Techniques and Applications
- RNA Research and Splicing
- Drug Transport and Resistance Mechanisms
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Wnt/β-catenin signaling in development and cancer
- Chronic Myeloid Leukemia Treatments
Institut Gustave Roussy
2018-2023
Laboratoire d'études sur les monothéismes
2023
Abstract Purpose: Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade cancer clinical behavior assess its relevance. Experimental Design: This a retrospective monocentric analysis centrally tested for genomic instability score (GIS) by MyChoice CDx (Myriad Genetics). detection...
ATP-binding cassette transporter (and specially P-glycoprotein) activity is a well known prognostic factor in acute myeloid leukemia, but when compared to other molecular markers its value has not been studied. Here we study relationships between this activity, fms-like tyro-sine kinase 3(FLT3/ITD), nucleophosmin(NPM1), CAAT-enhancer binding protein alpha(CEBPα), and brain leukemia cytoplasmic (BAALC), 111 patients with normal cytogenetics who underwent the same treatment, evaluate...
Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis inconclusive 15-19% of cases. Peritoneal fluid, available > 95% EOC cases, could serve as an alternative source cell-free (cftDNA) testing. Limited data show feasibility panel gene testing on ascites cfDNA but no study, to date, has investigated testing.We...
E-cadherin, a CDH1 gene product, is calcium-dependent cell–cell adhesion molecule playing critical role in the establishment of epithelial architecture, maintenance cell polarity, and differentiation. Germline pathogenic variants are associated with hereditary diffuse gastric cancer (HDGC), large rearrangements now being reported as well. Because could be breast (BC) susceptibility, also impact it. The aim our study to identify 148 BC cases no BRCA1 BRCA2 variants. To do so, zoom-in CGH...
<div>Abstract<p>Purpose: Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade OC clinical behavior assess its relevance. Design: This a retrospective monocentric analysis centrally tested for genomic-instability score (GIS) by MyChoice CDx (Myriad Genetics). detection quantification were...
<h3>Introduction/Background</h3> Knowledge regarding homologous recombination deficiency (HRD) status at diagnosis is essential to manage patients with advanced epithelial ovarian cancer (EOC). These genomic tests are performed on tumor samples and unfortunately the analysis of DNA missing 15–19% cases. <h3>Methodology</h3> We collected ascites or peritoneal washings (20ml) from 53 undergoing primary secondary laparoscopy for suspicion EOC, therapeutic paracentesis. A Cancer Gene Panel (CGP)...
Abstract Background: Knowledge regarding the homologous recombination deficiency (HRD) status at diagnosis is essential to manage patients (pts) with advanced epithelial ovarian cancer (EOC). HRD defined by either a BRCA1 or BRCA2 mutation, genomic instability (GI). These tests are performed on FFPE tumor samples and unfortunately non-contributive in 12-18% of cases. Advanced OC frequently presents ascites which could provide an alternative source Cell-free DNA (cftDNA). Methods: We...
<div>Abstract<p>Purpose: Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade OC clinical behavior assess its relevance. Design: This a retrospective monocentric analysis centrally tested for genomic-instability score (GIS) by MyChoice CDx (Myriad Genetics). detection quantification were...
<div>AbstractPurpose:<p>Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of <i>BRCA1</i> promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade cancer clinical behavior assess its relevance.</p>Experimental Design:<p>This a retrospective monocentric analysis centrally tested for genomic instability score (GIS) by...